Jack Allen
Stock Analyst at Baird
(1.53)
# 3,429
Out of 5,182 analysts
45
Total ratings
40%
Success rate
-7.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jack Allen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTLA Intellia Therapeutics | Maintains: Neutral | $7 → $13 | $13.04 | -0.31% | 3 | Apr 27, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $7 → $9 | $2.25 | +300.00% | 4 | Apr 14, 2026 | |
| ACLX Arcellx | Downgrades: Neutral | $106 → $115 | $115.07 | -0.06% | 6 | Feb 23, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $44 | $50.99 | -13.71% | 3 | Nov 11, 2025 | |
| VOR Vor Biopharma | Upgrades: Outperform | $20 → $64 | $14.12 | +353.26% | 5 | Oct 15, 2025 | |
| TSHA Taysha Gene Therapies | Maintains: Outperform | $7 → $12 | $6.46 | +85.76% | 5 | Oct 2, 2025 | |
| FATE Fate Therapeutics | Maintains: Neutral | $5 → $4 | $1.31 | +205.34% | 2 | May 14, 2025 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $80 → $40 | $11.14 | +259.07% | 2 | Nov 15, 2024 | |
| TIL Instil Bio | Reiterates: Outperform | $180 | $8.13 | +2,114.02% | 9 | Sep 16, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Outperform | $8 | $0.28 | +2,755.10% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $84 | $28.56 | +194.12% | 1 | Oct 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $1.55 | +222.58% | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $4.01 | - | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 → $9 | $3.76 | +139.36% | 1 | Oct 7, 2021 |
Intellia Therapeutics
Apr 27, 2026
Maintains: Neutral
Price Target: $7 → $13
Current: $13.04
Upside: -0.31%
Allogene Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $7 → $9
Current: $2.25
Upside: +300.00%
Arcellx
Feb 23, 2026
Downgrades: Neutral
Price Target: $106 → $115
Current: $115.07
Upside: -0.06%
CRISPR Therapeutics AG
Nov 11, 2025
Maintains: Neutral
Price Target: $52 → $44
Current: $50.99
Upside: -13.71%
Vor Biopharma
Oct 15, 2025
Upgrades: Outperform
Price Target: $20 → $64
Current: $14.12
Upside: +353.26%
Taysha Gene Therapies
Oct 2, 2025
Maintains: Outperform
Price Target: $7 → $12
Current: $6.46
Upside: +85.76%
Fate Therapeutics
May 14, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $1.31
Upside: +205.34%
MiNK Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $80 → $40
Current: $11.14
Upside: +259.07%
Instil Bio
Sep 16, 2024
Reiterates: Outperform
Price Target: $180
Current: $8.13
Upside: +2,114.02%
Mereo BioPharma Group
Jun 13, 2024
Initiates: Outperform
Price Target: $8
Current: $0.28
Upside: +2,755.10%
Oct 31, 2023
Initiates: Outperform
Price Target: $84
Current: $28.56
Upside: +194.12%
Nov 2, 2022
Initiates: Outperform
Price Target: $5
Current: $1.55
Upside: +222.58%
May 18, 2022
Upgrades: Outperform
Price Target: n/a
Current: $4.01
Upside: -
Oct 7, 2021
Upgrades: Outperform
Price Target: $6 → $9
Current: $3.76
Upside: +139.36%